Login to Your Account



Salt shaker: FDA trial hold on pain drug sodium hitch to help Cara rival Trevena?

By Randy Osborne
Staff Writer

Friday, February 26, 2016

It's too early to say whether Cara Therapeutics Inc.'s delay of its phase III adaptive pivotal trial with I.V. CR845 for postoperative pain will provide an edge for competitor Trevena Inc. with oliceridine.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription